These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 881153)

  • 21. Alternatives and developing countries.
    Milstien JB; Dellepiane N
    Dev Biol Stand; 1999; 101():203-8. PubMed ID: 10566794
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bio Farma vaccine production.
    Kaligis AJ
    Paediatr Indones; 1972 Oct; 12(10):427-46. PubMed ID: 4679479
    [No Abstract]   [Full Text] [Related]  

  • 23. [Testing of vaccines. The challenge of testing complex combination vaccines].
    Merkle A; Lechner H; Oppling V; Meyer H
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1188-92. PubMed ID: 25204275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulatory requirements for vaccine authorisation.
    Jones PG; Cowan G; Gravendyck M; Nagata T; Robinson S; Waits M
    Rev Sci Tech; 2007 Aug; 26(2):379-93. PubMed ID: 17892159
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A 4R concept for the safety testing of immunobiologicals.
    Cussler K
    Dev Biol Stand; 1999; 101():121-6. PubMed ID: 10566784
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Who Expert Committee on Biological Standardization.
    World Health Organization
    World Health Organ Tech Rep Ser; 2004; 926():1-109. PubMed ID: 15918537
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Detection of the adventitious agents in the evaluation of vaccine safety].
    Augustynowicz E; Lutyńska A
    Przegl Epidemiol; 2012; 66(4):643-9. PubMed ID: 23484394
    [TBL] [Abstract][Full Text] [Related]  

  • 28. European regulations relevant to the marketing and use of fish vaccines.
    Lee A
    Dev Biol Stand; 1997; 90():341-6. PubMed ID: 9270862
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitative detection of RT activity by PERT assay: feasibility and limits to a standardized screening assay for human vaccines.
    André M; Morgeaux S; Fuchs F
    Biologicals; 2000 Jun; 28(2):67-80. PubMed ID: 10885614
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Good manufacturing practice for immunological veterinary medicinal products.
    Todd JI
    Rev Sci Tech; 2007 Apr; 26(1):135-45. PubMed ID: 17633298
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulations for vaccines against emerging infections and agrobioterrorism in the United States of America.
    Elsken LA; Carr MY; Frana TS; Brake DA; Garland T; Smith K; Foley PL
    Rev Sci Tech; 2007 Aug; 26(2):429-41. PubMed ID: 17892163
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stability testing requirements for vaccines--draft guidelines of the International Conference on Harmonization.
    Haase M
    Dev Biol Stand; 1996; 87():309-18. PubMed ID: 8854031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. WHO Expert Committee on biological standardization.
    World Health Organ Tech Rep Ser; 2007; (941):1-340, back cover. PubMed ID: 18314862
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of adventitious viruses in biologicals--a rare occurrence.
    Nims RW
    Dev Biol (Basel); 2006; 123():153-64; discussion 183-97. PubMed ID: 16566443
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of methods used for detection of mycoplasma contamination in cell cultures, sera, and live-virus vaccines.
    Benisheva T; Sovová V; Ivanov I; Opalchenova G
    Folia Biol (Praha); 1993; 39(5):270-6. PubMed ID: 8206173
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Application of RT-PCR for the detection of avian reovirus contamination in avian viral vaccines.
    Bruhn S; Bruckner L; Ottiger HP
    J Virol Methods; 2005 Feb; 123(2):179-86. PubMed ID: 15620400
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Formulation, stability, and delivery of live attenuated vaccines for human use.
    Burke CJ; Hsu TA; Volkin DB
    Crit Rev Ther Drug Carrier Syst; 1999; 16(1):1-83. PubMed ID: 10099898
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Problems raising from the control of biological products employed in medicine. Control of sera, vaccines, and biological products in France].
    Desbordes J
    Ann Ist Super Sanita; 1969; 5(3-4):218-81. PubMed ID: 16089166
    [No Abstract]   [Full Text] [Related]  

  • 39. The consistency approach for the quality control of vaccines.
    Hendriksen C; Arciniega JL; Bruckner L; Chevalier M; Coppens E; Descamps J; Duchêne M; Dusek DM; Halder M; Kreeftenberg H; Maes A; Redhead K; Ravetkar SD; Spieser JM; Swam H
    Biologicals; 2008 Jan; 36(1):73-7. PubMed ID: 17892948
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effect of the Reorganization of Drug Legislation "Act" on the production and admission of infusion solutions].
    Mohrbutter K; Schnieders B; Schuster J; Wolff U
    Klin Anasthesiol Intensivther; 1977; (14):74-88. PubMed ID: 926693
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.